Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
From outside firms

Analysis and Perspectives

Commentary and analysis from outside consulting and policy firms. Not part of Medicaid Monitor's independently scored news coverage. Each piece links back to the firm's original publication.

Milliman · Nov 16

Milliman Outlines Framework for Rural Medicaid Value-Based Payment Design

This Milliman white paper argues that value-based payment models designed for urban health systems often fail in rural settings due to smaller patient populations, limited provider supply, and resource constraints. It proposes a five-part framework for Medicaid leaders covering financial risk calibration, access-focused incentive structures, performance measurement adjustments for low patient volume, attribution tailored to rural care patterns, and realistic benchmark-setting. The analysis is directly relevant to Medicaid directors and MCOs designing or expanding VBP arrangements with rural provider networks.

Read at milliman.com →
Milliman · Nov 10

Medicare Drug Price Negotiations Reshape PACE Pharmacy Economics

The analysis explains how Medicare's maximum fair price (MFP) negotiations, now expanding to Part B drugs in 2028, are altering pharmacy cost and revenue dynamics for PACE organizations, which serve frail dual-eligible seniors often overlapping with Medicaid managed care populations. It cautions that lower negotiated drug prices do not automatically improve margins because of complex interactions with rebates, 340B pricing, and CMS's Part D reconciliation process, urging PACE organizations to closely monitor utilization and net costs as more drugs become subject to MFP.

milliman.com →
Milliman · Nov 10

How PACE Organizations Build Their Medicare Part D Drug Coverage Bids

This piece explains the process PACE (Program of All-Inclusive Care for the Elderly) organizations follow to develop and submit their annual Medicare Part D bids to CMS, covering required documentation, bid pricing tools, and how projected drug costs, administrative expenses, and margin are built into the bid. Because PACE serves dually eligible seniors who also rely on Medicaid for long-term services and supports, the financial mechanics described here intersect with state Medicaid LTSS financing even though the bid itself is a Medicare process.

milliman.com →
Milliman · Nov 10

What PACE Plans Need to Know About CMS's New V28 Risk Model

Milliman explains the shift from the 2017 CMS-HCC (V22) to the 2024 CMS-HCC (V28) risk adjustment model for PACE organizations, detailing how CMS rebuilt condition categories directly on ICD-10 codes and applied stricter exclusion rules for discretionary diagnoses. These structural changes reduce the number of diagnosis codes mapped to payment HCCs, which affects risk score calculations and revenue for PACE plans, a Medicaid- and Medicare-funded long-term services and supports program serving frail elderly populations.

milliman.com →
Milliman · Nov 10

How PACE Plans Must Track Part D Manufacturer Discounts Under the IRA

This Milliman analysis explains how the Inflation Reduction Act's Manufacturer Discount Program affects PACE organizations, which serve dually eligible frail older adults and blend Medicaid and Medicare financing. It walks through two payment tracks, CMS's prospective MDP subsidy and reconciliation process, and manufacturer invoicing, highlighting new cash flow, reserving, and oversight considerations for PACE actuaries and finance teams. While focused on Part D rather than core Medicaid managed care rules, it matters to Medicaid stakeholders because PACE programs are jointly financed and often administered alongside state Medicaid managed care oversight.

milliman.com →
Milliman · Nov 10

How PACE Organizations Can Navigate Medicaid Rate Renewals

The piece explains how state Medicaid agencies set capitation rates for PACE (Program of All-Inclusive Care for the Elderly) organizations, centered on the "amount that would have otherwise been paid" benchmark and CMS's December 2024 rate-setting guidance. It walks through practical considerations, such as population frailty adjustments and data sources used to build the AWOP, that PACE organizations should understand when engaging with state Medicaid agencies during rate renewal negotiations. This matters for Medicaid managed care and LTSS stakeholders because it affects how frail, high-need dual-eligible populations are financed and how states balance cost-effectiveness with adequate rates.

milliman.com →
Milliman · Nov 10

How Medicaid Rates Are Set for PACE Programs Serving Dual-Eligible Seniors

This explainer breaks down how PACE organizations are reimbursed, focusing on how state Medicaid agencies set capitation rates using either experience-based methodologies or a negotiated percentage of the Amount That Would Have Otherwise Been Paid (AWOP). It also covers how rates can vary by participant characteristics like age, Medicare status, and geography, offering useful background for actuaries and state officials working on PACE rate-setting and cost-effectiveness demonstrations required under Medicaid rules.

milliman.com →
Milliman · Nov 2

Rethinking Medicaid Payment Rates for Tech-Enabled Home Care Services

This Milliman white paper examines how state Medicaid agencies should design payment models for technology-based home and community-based services (HCBS), such as remote monitoring and assistive devices, which carry different cost structures than traditional direct-care staffing models. It walks through the rate component build-up approach, discusses funding sources like ARPA and rural health initiatives, and outlines considerations for ensuring rates support access, quality, and person-centered care goals. The analysis is relevant to Medicaid LTSS policymakers and MCOs managing HCBS benefits as technology adoption expands.

milliman.com →
Milliman · Oct 30

Mapping Racial Disparities in Provider Access Across U.S. Counties

This Milliman white paper uses HRSA's Area Health Resource Files and an enhanced floating catchment area method to measure how access to physicians and specialists varies by county and correlates with racial composition. It finds meaningful gaps in provider access tied to race and geography, which is relevant context for Medicaid managed care plans and regulators focused on network adequacy and health equity, even though the analysis is not Medicaid-specific.

milliman.com →
Milliman · Oct 22

340B Drug Pricing Reform Could Ripple Into Medicaid Drug Pricing Dynamics

Milliman's white paper examines the rapid growth of the 340B Drug Pricing Program and CMS's proposed CY2027 OPPS rule to cut Medicare Part B 340B drug payments, noting the program's deep interconnection with Medicaid Best Price requirements and Medicare Maximum Fair Price policy. While the analysis is primarily focused on Medicare outpatient reimbursement and hospital financial impacts, it flags downstream effects relevant to drug pricing stakeholders broadly, including those managing Medicaid pharmacy benefit and rebate calculations. Medicaid managed care plans with pharmacy benefit responsibilities may need to track these reforms given the programs' interlocking statutory ceiling price mechanics.

milliman.com →
Milliman · Oct 21

Oncology Drug Spending Set to Double by 2030, Spanning Medicare, Medicaid, and Commercial Markets

Milliman projects U.S. oncology drug spending will grow from roughly $200 billion in 2025 to over $400 billion by 2030, driven by pipeline launches, expanded indications, and the unique dynamic of oncology drugs spanning both medical and pharmacy benefits. The paper discusses how Medicare's Inflation Reduction Act drug price negotiation program and evolving generic/biosimilar competition will reshape costs across Medicare, commercial, and Medicaid markets, which matters for Medicaid pharmacy benefit managers and MCOs managing specialty drug spend, though Medicaid-specific dynamics are not the primary focus.

milliman.com →
Milliman · Oct 19

California Pushes Dual-Eligible Members Into Integrated D-SNP Plans

This Milliman white paper examines California's shift from Medicare-Medicaid Plans to exclusively aligned enrollment D-SNPs (Medi-Medi Plans) under the CalAIM initiative, tracing enrollment growth and the state's restrictions on non-integrated D-SNPs that have driven market exits and consolidation. It matters for Medicaid managed care stakeholders because it illustrates how state policy levers can reshape dual-eligible plan markets and force alignment between Medicare Advantage and Medicaid managed care plans under common parent organizations.

milliman.com →
Milliman · Oct 16

New CMS Rules Tighten the Math Behind 1115 Medicaid Waivers

Milliman examines how H.R. 1 and new CMS guidance overhaul budget neutrality requirements for Section 1115 Medicaid demonstrations, including a new requirement that the CMS Chief Actuary certify demonstrations won't increase federal spending, tighter limits on hypothetical spending assumptions, and restrictions on carrying forward savings across renewal periods. The paper lays out five actions states can take before the January 1, 2027 effective date to protect existing waivers covering health-related social needs, coverage expansions, and other initiatives. This matters for state Medicaid agencies and MCOs because it reshapes the feasibility and design of future waiver-based innovations.

milliman.com →
Milliman · Oct 12

Medicare's Maximum Fair Price Shakes Up Pharmacy Dispensing Economics

Milliman examines how Medicare Part D's Maximum Fair Price (MFP) program, created under the Inflation Reduction Act, is altering pharmacy stocking and dispensing incentives as manufacturers choose different refund benchmarks for negotiated drugs. The analysis finds that the refund mechanism design, more than the negotiated price itself, determines whether dispensing specialty drugs remains viable for small and independent pharmacies, with ripple effects across entire therapeutic classes. While centered on Medicare rather than Medicaid, the pharmacy reimbursement and specialty drug dynamics discussed carry indirect relevance for Medicaid pharmacy benefit managers and managed care plans monitoring parallel drug pricing pressures.

milliman.com →
Milliman · Oct 7

New 2027 CPT Maternity Codes Force Payers to Rebuild Reimbursement Models

Milliman explains that the 2027 CPT Editorial Panel overhaul replaces the long-standing global maternity bundle with granular codes for antepartum, labor, delivery, and postpartum services, requiring payers to rethink fee schedules rather than simply mapping old rates onto new codes. For Medicaid MCOs, which cover a large share of U.S. births, this shift has major implications for provider reimbursement design, total maternity cost trends, and member cost-sharing calculations under the new coding framework.

milliman.com →
Milliman · Sep 10

Milliman Reviews a Decade of Cell and Gene Therapy Cost Forecasting for Payers

Milliman examines ten years of actual cell and gene therapy (CGT) market experience versus early payer expectations, finding that the anticipated wave of approvals and utilization never materialized as predicted, though costs remain high and unpredictable. The paper proposes forecasting methods using manufacturer revenue data rather than claims alone, and offers case studies on Zolgensma and Elevidys to illustrate volatility in uptake—insights relevant to any payer, including Medicaid MCOs, managing specialty drug risk and benefit design.

milliman.com →
Milliman · Aug 14

Milliman proposes provider partnership approach to reduce waste and abuse beyond fraud enforcement

This white paper argues that while fraud enforcement in healthcare has reached record levels, waste and abuse represent larger sources of overspending that require different strategies than traditional program integrity approaches. The authors distinguish between fraud, waste, and abuse as separate problems requiring tailored solutions, and propose five evidence-based approaches for Medicaid and Medicare payers to address waste and abuse through collaboration with providers rather than purely adversarial enforcement. The analysis is particularly relevant for MCO compliance teams balancing program integrity requirements with provider network relationships.

milliman.com →
Milliman · Aug 13

New CMS Rule Would Tighten Medicare-Based Limits on State Directed Payments

Milliman examines CMS's proposed rule implementing a 2025 law that replaces the old "average commercial rate" cap with a new Medicare-based payment limit for Medicaid state-directed payments and targeted fee-for-service practitioner payments. The paper details the technical complexity of building per-service Medicare limit calculations—including provider mappings, fee schedule crosswalks, and a three-tier comparator approach—and urges states to begin preparation now ahead of phased 2027-2029 compliance deadlines. This has major implications for how states and MCOs structure and justify SDP arrangements going forward.

milliman.com →
Milliman · Aug 6

GLP-1 Drug Spending Surge Forces Payers—Including Medicaid—to Rethink Coverage Strategy

Milliman examines the rapid growth of GLP-1 medication spending (from $13.7B to $71.7B in five years) and lays out considerations for payers on benefit design, utilization management, and total cost of care rather than just unit price. While the analysis spans commercial, Medicare, and Medicaid markets broadly, it has direct relevance for Medicaid MCOs and state programs grappling with obesity drug coverage mandates and cost containment, and links to related Milliman work specifically on Medicaid anti-obesity medication coverage.

milliman.com →
Milliman · Jun 29

Medicaid MCO Underwriting Margins Nearly Break Even in 2025 After Two Years of Decline

Milliman's 18th annual benchmarking report analyzes financial performance for 186 Medicaid MCOs representing $305 billion in revenue, finding composite underwriting margins improved slightly to -0.1% in 2025 from -0.6% in 2024, though still well below the 2.5-3.5% gains seen during 2021-2023. The report shows medical loss ratios at 94.3%, declining risk-based capital ratios, and administrative costs rising on a per-member basis as enrollment fell post-PHE unwinding, providing state directors and MCO executives critical benchmarks for assessing rate adequacy and financial health heading into 2026.

milliman.com →

Get the daily briefing.